Page 4 - Astrazeneca

EU says people vaccinated with AstraZeneca should be able to travel to US

The EU has its own safe-travel list, from which the United States was recently removed after a spike in infections there.

UK approves Pfizer, AstraZeneca vaccines as booster doses for Covid-19

The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.

Astrazeneca and European Union strike deal to end vaccine supply dispute

The deal ends a blame game over the EU's slow start in vaccinating its 448 million population

Better than booster shots, non-vaccines promise to build Covid immunity

Monoclonal antibodies boost immune response to infections by binding to particular sites on the spike protein of the virus that causes Covid-19.

No plan yet to revise Covishield 84-day dose gap, clarifies govt

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports

SII informs Centre it will supply around 200 mn Covishield doses in Sep

SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said

India to resume Covid vaccine exports in 2022: Head of govt expert panel

A second wave of Covil infections and local supply delays prompted the government to prioritize its own citizens and halted overseas shipments of vaccines in April.

Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF

Preliminary results from Azerbaijan trials have been announced

AstraZeneca's antibody drug prevents Covid-19 in high-risk groups

Results from Astra's study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday

Pfizer and Astra vaccines less effective after 90 days, says study

The Oxford University study found that 90 days after a second shot of the Pfizer or Astra vaccine, their efficacy in preventing infections had slipped to 75 per cent and 61 per cent, respectively

Pfizer, AstraZeneca vaccines less effective against Delta variant: Study

The COVID vaccines by Pfizer and AstraZeneca are less effective against the Delta variant compared to the Alpha variant, according to a study led by researchers at the University of Oxford

AstraZeneca Pharma India Q1 net profit declines 45% to Rs 10.24 cr

Drug firm AstraZeneca Pharma India on Monday reported a 45.03 per cent decline in its net profit to Rs 10.24 crore for the June ended quarter

Nepal receives first batch of AstraZeneca vaccine against Covid from Japan

Nepal received the first batch of AstraZeneca COVID-19 vaccine from Japan on Saturday, local media reports said.

Combining AstraZeneca and mRNA Covid vaccines is effective: Danish study

A growing number of countries are looking at switching to different Covid vaccines for second doses, a measure necessary in Denmark after health authorities discontinued AstraZeneca's vaccine in April

AstraZeneca's nasal vax prevents Covid spread in animal models

The trial, led by researchers including from the US National Institutes of Health (NIH) and the University of Oxford, UK, was published in the journal Science Translational Medicine.

Over 18 and considering the AstraZeneca vaccine? This may help you decide

Let's look at the evidence

Astra's Covid-19 vaccine sales triple in Q2, top $1 billion in H1

Firm exploring whether vaccine biz is sustainable for next 5-10 years: Official

Covishield single jab efficacy drops after 16 weeks in 60+ age grp: Report

The efficacy of the single dose of Oxford-Astrazeneca Covid-19 vaccine Covishield dropped at 16 weeks for those above the age of 60

AstraZeneca to apply for Covid-19 vaccine approval in US later in 2021

AstraZeneca reported first-half revenue of $15.5 billion, up 23 per cent

AstraZeneca finds small clot risk after first dose of Vaxzevria vaccine

No extra risk after second dose shows study led and funded by drug maker